Arazlo lotion launched in US for acne treatment

Arazlo lotion has been released for commercial distribution in the United States, Ortho Dermatologics announced in a press release.

The first tazarotene acne treatment available in lotion formulation, Arazlo (tazarotene 0.045%) was approved by the FDA in December 2019.

“Retinoids like tazarotene are highly effective in treating acne and considered a cornerstone of acne treatment, but often are perceived to be associated with skin irritation. Clinical studies have demonstrated that Arazlo’s proprietary formulation provides the proven efficacy of a retinoid in a lotion that is more tolerable to patients than a higher concentration tazarotene,” Bill Humphries, president of Ortho Dermatologics, said in the release.

The medication is available via prescription for people aged 9 and older with acne. Its price is comparable to other branded acne products, according to the release.